Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $30.00 price target on Entrada Therapeutics (NASDAQ: TRDA) The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE